OptiNose, Inc. (OPTN) Surged to All Time High at $28.26

June 29, 2018 - By Mary Bollinger

OptiNose, Inc. (NASDAQ:OPTN) touched $28.26 price per share on Jun, 29, also an all time high. This chart pattern was announced by Barchart.com. OptiNose, Inc. (NASDAQ:OPTN) has $1.15 billion MC. The valuation of NASDAQ:OPTN can change by $57.65M if our $29.67 price target is touched.

OPTN is reaching $28.26 during the last trading session, after decreased 0.70%.Currently OptiNose, Inc. is after 0.00% change in last June 29, 2017. OPTN has also 46,133 shares volume. The stock underperformed the S&P500 by 12.57%.

OptiNose, Inc. (NASDAQ:OPTN) is expected to reveal earnings on August, 13., RTT reports. After $-0.81 EPS was reported last quarter, analysts now see EPS growth of -2.47 % for OptiNose, Inc..

For more OptiNose, Inc. (NASDAQ:OPTN) news posted briefly go to: Globenewswire.com, Nasdaq.com, Benzinga.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “Optinose Announces Pricing of Public Offering of Common Stock” posted on June 07, 2018, “Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The …” on June 15, 2018, “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” with a publish date: June 29, 2018, “Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals” and the last “Optinose Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional …” with publication date: June 11, 2018.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States.The firm is valued at $1.15 billion. The firm offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.Currently it has negative earnings. It also markets Onzetra Xsail for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: